Abbott Laboratories $ABT Shares Sold by Lombard Odier Asset Management Europe Ltd

Key Points

• Lombard Odier Asset Management Europe Ltd cut its Abbott Laboratories stake by 76.8% in the fourth quarter, selling 58,606 shares and leaving it with 17,750 shares worth about $2.22 million.
• Abbott reported better-than-expected quarterly results, with EPS of $1.15 versus the $1.14 estimate and revenue of $11.16 billion, up 7.8% year over year. The company also reiterated guidance for FY 2026 and Q2 2026.
• Despite multiple analyst price target cuts, Abbott still carries a consensus rating of Moderate Buy and a consensus price target of $118.30. The stock recently traded at $90.64 and also supports a quarterly dividend of $0.63 per share.

Lombard Odier Asset Management Europe Ltd lowered its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 76.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,750 shares of the healthcare product maker's stock after selling 58,606 shares during the period. Lombard Odier Asset Management Europe Ltd's holdings in Abbott Laboratories were worth $2,224,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC grew its position in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock valued at $648,000 after buying an additional 162 shares during the last quarter. United Bank raised its stake in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after acquiring an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC lifted its position in Abbott Laboratories by 13.6% in the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after acquiring an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after acquiring an additional 292,547 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ABT shares. JPMorgan Chase & Co. reduced their price objective on Abbott Laboratories from $123.00 to $110.00 and set an "overweight" rating for the company in a research note on Friday, April 17th. Piper Sandler reduced their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, April 17th. Jefferies Financial Group reduced their price target on Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating for the company in a report on Friday, April 17th. Wells Fargo & Company cut their price objective on Abbott Laboratories from $122.00 to $109.00 and set an "overweight" rating for the company in a research report on Friday, April 17th. Finally, UBS Group lowered their price target on shares of Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating on the stock in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $118.30.

Abbott Laboratories Trading Up 2.2%

NYSE:ABT opened at $90.64 on Wednesday. The company has a market capitalization of $157.87 billion, a PE ratio of 25.39, a price-to-earnings-growth ratio of 1.53 and a beta of 0.63. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06. The stock has a fifty day simple moving average of $90.93 and a 200-day simple moving average of $107.30. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period last year, the firm posted $1.09 EPS. The firm's revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. Abbott Laboratories's dividend payout ratio is presently 70.59%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company's stock, valued at $201,300. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.